Imagine a silent intruder hiding in the prostate, masquerading as cancer. That's the reality of prostatic tuberculosis, a rare and often overlooked condition. While tuberculosis primarily affects the lungs, it can stealthily spread to other parts of the body, including the prostate. But here's where it gets controversial: its symptoms are so nonspecific that it's frequently misdiagnosed, leading to delayed treatment and potential complications. Let's dive into a fascinating case report that sheds light on this enigmatic disease.
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, remains a global health concern. In 2020, the World Health Organization (WHO) reported 9.9 million new cases and 1.5 million deaths worldwide. While pulmonary tuberculosis dominates, extrapulmonary forms account for about 15% of cases, with urogenital tuberculosis making up 10 to 14% of these. Among these, prostatic tuberculosis is exceptionally rare, even in regions where tuberculosis is endemic. Its vague symptoms—such as urinary discomfort, frequent urination, or retention—often mimic other conditions, making diagnosis a challenge. It’s typically discovered incidentally, as in the case we’re about to explore.
Case in Point: A 69-year-old man with no known history of tuberculosis presented with acute urinary retention and irritative urinary symptoms. A digital rectal exam revealed an enlarged, firm, nodular prostate, and his PSA level was elevated at 27 ng/ml. Pelvic ultrasound confirmed an enlarged prostate, estimated at 90 ml. Following adenomectomy for suspected hypertrophy, the surgical specimen appeared nodular, whitish, and firm, with yellowish areas. Histological examination unveiled a surprising truth: the prostate showed mixed glandular and myomatous hyperplasia without signs of malignancy, but it was accompanied by granulomatous inflammation, epithelioid cells, Langhans giant cells, and caseous necrosis. The diagnosis? Caseous follicular tuberculosis of the prostate, coexisting with adenomyomatous hyperplasia. The patient was started on antituberculous chemotherapy, including Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol for 2 months, followed by Isoniazid and Rifampicin for 4 months. Interestingly, there was no evidence of tuberculosis elsewhere in his body.
And this is the part most people miss: Prostatic tuberculosis accounts for less than 2% of urogenital tuberculosis cases, yet its clinical presentation often mimics prostate cancer. In regions like Madagascar, Senegal, Morocco, and Indonesia, only a handful of cases have been reported in recent years, highlighting its rarity. The bacterium typically reaches the prostate through the bloodstream from a pulmonary or renal source, though spread from nearby structures like the seminal vesicles is less common. Rarely, it can even occur after BCG therapy for bladder cancer. Our patient had no history of tuberculosis, underscoring the importance of considering this diagnosis even in the absence of obvious risk factors.
Diagnosis relies heavily on histopathological examination, as imaging like ultrasound, while helpful, lacks specificity. Microscopic findings of epithelioid and giant cell granulomas with caseous necrosis are key, and PCR testing (GeneXpert MTB/RIF) boosts diagnostic sensitivity to 95%. Treatment follows the standard regimen for extrapulmonary tuberculosis, emphasizing the need for early detection and prompt intervention.
Here’s the takeaway: Prostatic tuberculosis, though rare, should be on the radar for any atypical prostatic hypertrophy, especially in high-prevalence regions. Its clinical and biological similarities to cancer demand systematic histological confirmation. But here’s a thought-provoking question: With its nonspecific symptoms and rarity, how often is prostatic tuberculosis misdiagnosed or overlooked, potentially leading to unnecessary procedures or delayed treatment? Share your thoughts in the comments—let’s spark a discussion!
